Catalyst Dossier · compiled by CeliA 🧫
Amgen Inc. (AMGN)
Biological Products, (No Diagnostic Substances) · market cap $182.2B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-30 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Amgen Inc. (AMGN) is a large-cap biopharmaceutical company with $36.8B in 2025 revenue, a diversified pipeline spanning oncology, inflammation, and bone disease, and a market cap of ~$196B. Its lead pipeline asset is tarlatamab, a DLL3xCD3 BiTE antibody in Phase 3 for small cell lung cancer (SCLC), carrying orphan, fast-track, and breakthrough designations. The company carries significant net debt of ~$50.7B, largely reflecting the 2023 Horizon Therapeutics acquisition, but generates substantial free cash flow to service it.
The catalyst path
- 2026-09-30 (est.)Phase 3 · Pegaspargaseimp 9/10
- 2026-10-18 (est.)Phase 2 · Tarlatamabimp 7/10
- 2026-10-31 (est.)Phase 2 · AMG 193imp 7/10
- 2026-11-30 (est.)Phase 2 · Anvumetostatimp 7/10
- 2026-12-14 (est.)Phase 3 · ABP 234imp 9/10
- 2027-01-06 (est.)Phase 2 · AMG 732imp 7/10
- 2027-01-15 (est.)Phase 2 · pegfilgrastimimp 7/10
- 2027-01-21 (est.)Phase 3 · Maridebart cafraglutideimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Rozibafusp Alfa | Phase 2 | Systemic Lupus Erythematosus (SLE) |
| Lumakras | Approved | KRAS G12C NSCLC |
| Tarlatamab | Phase 3 | Small Cell Lung Cancer |
| AMG 509 | Phase 1 | Prostate Cancer |
| Etanercept Liquid | Phase 3 | Rheumatoid Arthritis |
| Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments | Phase 2 | Temporomandibular Disorder |
| Vinblastine sulfate | Phase 2 | HIV Infections |
| PEG asparaginase | Phase 2 | Lymphoblastic Leukemia |
| romosozumab HCP administration with PFS | Phase 3 | Post-Menopausal Osteoporosis |
| AMG 102 and erlotinib | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| Anvumetostat | Phase 2 | Advanced MTAP-null Solid Tumors |
| Panitumumab + FOLFOX (DP) | Phase 2 | Metastatic Colorectal Cancer |
| CC10004 | Phase 2 | Psoriasis |
| Denosumab (AMG 162) | Phase 3 | Postmenopausal Osteoporosis |
| Filgrastim-SD/01 | Phase 2 | Non-small Cell Lung Cancer |
| Mitozantrone | Phase 2 | Non-Hodgkin's Lymphoma |
| Pegaspargase | Phase 3 | Acute Lymphoblastic Leukemia |
| Alendronate Effervescent Oral Tablet | Phase 2 | Erosive Osteoarthritis |
| Pegfilgrastim (Neulasta) | Phase 2 | Multiple Myeloma |
| AMG 162 / Denosumab | Phase 3 | Breast Cancer |
Price & technical context
3-month
+14.2%
6-month
+10.2%
12-month
+40.4%
52-wk range
$271.18–$444.12
vs 50-day MA
-3.7%
vs 200-day MA
+7.0%
Realized vol
29.4%
Max drawdown
-23.4%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AMGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.